The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approved for ...

A seismic shift in pediatric medical care has arrived with the FDA’s approval of Ryoncil (remestemcel-L-rknd), a ...

While gene therapy has emerged as a promising alternative for treating beta-thalassemia, hematopoietic stem cell ...

Meiji Seika Pharma establishes local subsidiary “Taiwan Meiji Pharma Co., Ltd.” in Taiwan: Tokyo Friday, December 27, 2024, 13:00 Hrs [IST] Meiji Seika Pharma Co., Ltd., a pha ...

The drug and biotech sector had a turbulent year in 2024, starting strong but losing momentum in the second half. This ...

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

Apraglutide is under clinical development by Ironwood Pharmaceuticals and currently in Phase III for Short Bowel Syndrome.

Email Alerts for: Current price: $2.63 Market cap: $3.93bn Current price: $3.01 Current price: $2.31 Current price: $3.69 ...

Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, President: Daikichiro Kobayashi) announced the establishment of a local subsidiary, "Taiwan Meiji Pharma Co., Ltd." (Headquarters: Taipei ...

Kamilia Smith, MD, FACOG, NCMP, discusses how societal stigma and cultural misconceptions about menopause, combined with widespread misinformation about treatment options, create significant barriers ...

New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!

Patent for methods of use of topical DNase enzymes in the eye covers L304, Neutrolis’ proprietary therapy in development for ...